Anticoagulant therapy: Current status and shortcomings

Seminars in Interventional Radiology

Volumn 18, Issue 2, 2001, Pages 113-118

  Strandness D E , Jr ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Deep venous thrombosis; Post thrombotic syndrome; Treatment

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; DEEP VEIN THROMBOSIS; FIBRINOLYTIC THERAPY; HOSPITALIZATION; HUMAN; POSTTHROMBOSIS SYNDROME; REVIEW; THROMBOEMBOLISM; VEIN VALVE;

EID: 0034978149     PISSN: 07399529     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15172     Document Type: Review

References (31)

1. Low-molecular weight heparin treatment of venous thromboembolism
2. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: Outcome of therapy and health economy aspects-low-molecular-weight heparin versus unfractionated heparin
3. Prevention of recurrences after deep venous thrombosis: Role of low-molecular-weight heparins
4. Unfractionated heparin and low-molecular-weight heparin for the initial treatment of acute venous thromboembolism
5. Deep venous insufficiency: The relationship between lysis and subsequent reflux
6. Propagation rethrombosis and new thrombus formation
7. The relationship of venous diameter to reflux, cephalad thrombus and cephalad reflux following deep venous thrombosis
8. Valvular reflux after deep vein thrombosis: Incidence and time of occurrence
9. Diagnosis of deep venous thrombosis: A prospective study comparing duplex scanning to contrast venography
10. Venous duplex scanning of the leg: Range, variability and reproducibility
11. Uber die erweiterung kleinerer gefasse
12. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance - A multicenter collaborative family study
13. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation
14. Incidence of venous thromboembolism in families with inherited thrombophilia
15. Risk of venous thromboembolism with third-generation oral contraceptives: A review
16. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis
17. The natural history of deep-vein thrombosis
18. Heparin in patients with venous thromboembolism and contraindications to oral anticoagulant therapy
19. Treatment and prevention of venous thromboembolism
20. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
21. Treatment of venous thromboembolism in cancer patients
22. Venous thrombus stability during acute phase of therapy
23. Low-molecular-weight heparin therapy and mortality
24. First workshop for detection of heparin-induced antibodies: Validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA
25. The long-term clinical course of acute deep venous thrombosis
26. Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation?
27. Oral Anticoagulants-mechanism of action, clinical effectiveness, and optimal therapeutic range
28. Hemorrhagic complications of anticoagulant therapy
29. Heparin and low-molecular weight heparin
30. Is the postphlebitic leg always postphlebitic? Relation between phlebographic appearance and late sequelae
31. Long-term sequlae of acute venous thrombosis